178 related articles for article (PubMed ID: 26322676)
1. Risk of Hypertension With Sorafenib Use in Patients With Cancer: A Meta-Analysis From 20,494 Patients.
Yang X; Pan X; Cheng X; Kuang Y; Cheng Y
Am J Ther; 2017; 24(1):e81-e101. PubMed ID: 26322676
[TBL] [Abstract][Full Text] [Related]
2. Risk of hypertension in cancer patients treated with sorafenib: an updated systematic review and meta-analysis.
Funakoshi T; Latif A; Galsky MD
J Hum Hypertens; 2013 Oct; 27(10):601-11. PubMed ID: 23636006
[TBL] [Abstract][Full Text] [Related]
3. Incidence and risk of sorafenib-induced hypertension: a systematic review and meta-analysis.
Li Y; Li S; Zhu Y; Liang X; Meng H; Chen J; Zhang D; Guo H; Shi B
J Clin Hypertens (Greenwich); 2014 Mar; 16(3):177-85. PubMed ID: 24621095
[TBL] [Abstract][Full Text] [Related]
4. Risk of treatment-related mortality with sorafenib in cancer patients: a meta-analysis of 20 randomly controlled trials : Risk of sorafenib-associated death.
Yang X; Pan X; Cheng X; Cheng Y; Kuang Y
Int J Clin Pharm; 2015 Dec; 37(6):1047-56. PubMed ID: 26173936
[TBL] [Abstract][Full Text] [Related]
5. Safety and tolerability of sorafenib in patients with radioiodine-refractory thyroid cancer.
Worden F; Fassnacht M; Shi Y; Hadjieva T; Bonichon F; Gao M; Fugazzola L; Ando Y; Hasegawa Y; Park DJ; Shong YK; Smit JW; Chung J; Kappeler C; Meinhardt G; Schlumberger M; Brose MS
Endocr Relat Cancer; 2015 Dec; 22(6):877-87. PubMed ID: 26370187
[TBL] [Abstract][Full Text] [Related]
6. Exposure-toxicity relationship of sorafenib in Japanese patients with renal cell carcinoma and hepatocellular carcinoma.
Fukudo M; Ito T; Mizuno T; Shinsako K; Hatano E; Uemoto S; Kamba T; Yamasaki T; Ogawa O; Seno H; Chiba T; Matsubara K
Clin Pharmacokinet; 2014 Feb; 53(2):185-96. PubMed ID: 24135988
[TBL] [Abstract][Full Text] [Related]
7. Sorafenib or sunitinib as postoperative adjuvant therapy for Chinese patients with locally advanced clear cell renal cell carcinoma at high risk for disease recurrence.
Zhao J; Zhu Y; Zhang C; Wang X; He H; Wang H; Wu Y; Zhou W; Shen Z
Urol Oncol; 2013 Nov; 31(8):1800-5. PubMed ID: 22658883
[TBL] [Abstract][Full Text] [Related]
8. Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial.
Hutson TE; Lesovoy V; Al-Shukri S; Stus VP; Lipatov ON; Bair AH; Rosbrook B; Chen C; Kim S; Vogelzang NJ
Lancet Oncol; 2013 Dec; 14(13):1287-94. PubMed ID: 24206640
[TBL] [Abstract][Full Text] [Related]
9. Skin cancer associated with the use of sorafenib and sunitinib for renal cell carcinoma.
Breaker K; Naam M; La Rosa FG; Flaig IP; Flaig TW
Dermatol Surg; 2013 Jul; 39(7):981-7. PubMed ID: 23464361
[TBL] [Abstract][Full Text] [Related]
10. Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis.
Wu S; Chen JJ; Kudelka A; Lu J; Zhu X
Lancet Oncol; 2008 Feb; 9(2):117-23. PubMed ID: 18221915
[TBL] [Abstract][Full Text] [Related]
11. Incidence and risk of hypertension with lenvatinib in treatment of solid tumors: An updated systematic review and meta-analysis.
Wu H; Ding X; Zhang Y; Li W; Chen J
J Clin Hypertens (Greenwich); 2022 Jun; 24(6):667-676. PubMed ID: 35538636
[TBL] [Abstract][Full Text] [Related]
12. Cardiovascular comorbidities for prediction of progression-free survival in patients with metastatic renal cell carcinoma treated with sorafenib.
Szmit S; Zaborowska M; Waśko-Grabowska A; Żołnierek J; Nurzyński P; Filipiak KJ; Opolski G; Szczylik C
Kidney Blood Press Res; 2012; 35(6):468-76. PubMed ID: 22688785
[TBL] [Abstract][Full Text] [Related]
13. Frequent dose interruptions are required for patients receiving oral kinase inhibitor therapy for advanced renal cell carcinoma.
La Vine DB; Coleman TA; Davis CH; Carbonell CE; Davis WB
Am J Clin Oncol; 2010 Jun; 33(3):217-20. PubMed ID: 19745694
[TBL] [Abstract][Full Text] [Related]
14. Treatment-related fatigue with sorafenib, sunitinib and pazopanib in patients with advanced solid tumors: an up-to-date review and meta-analysis of clinical trials.
Santoni M; Conti A; Massari F; Arnaldi G; Iacovelli R; Rizzo M; De Giorgi U; Trementino L; Procopio G; Tortora G; Cascinu S
Int J Cancer; 2015 Jan; 136(1):1-10. PubMed ID: 24415642
[TBL] [Abstract][Full Text] [Related]
15. Sorafenib (NEXAVAR) and differentiated thyroid cancer. Toxic, and no proof of improved survival.
Prescrire Int; 2016 Feb; 25(168):37. PubMed ID: 27042725
[TBL] [Abstract][Full Text] [Related]
16. Risk of gastrointestinal events with sorafenib, sunitinib and pazopanib in patients with solid tumors: a systematic review and meta-analysis of clinical trials.
Santoni M; Conti A; De Giorgi U; Iacovelli R; Pantano F; Burattini L; Muzzonigro G; Berardi R; Santini D; Cascinu S
Int J Cancer; 2014 Aug; 135(4):763-73. PubMed ID: 24127298
[TBL] [Abstract][Full Text] [Related]
17. The adverse effects of sorafenib in patients with advanced cancers.
Li Y; Gao ZH; Qu XJ
Basic Clin Pharmacol Toxicol; 2015 Mar; 116(3):216-21. PubMed ID: 25495944
[TBL] [Abstract][Full Text] [Related]
18. Sorafenib in the treatment of radioiodine-refractory differentiated thyroid cancer: a meta-analysis.
Shen CT; Qiu ZL; Luo QY
Endocr Relat Cancer; 2014 Apr; 21(2):253-61. PubMed ID: 24302666
[TBL] [Abstract][Full Text] [Related]
19. [Three Patients with Acute Myocardial Infarction Associated with Targeted Therapy of Sorafenib for Metastatic Renal Cell Carcinoma : Case Report].
Takagi K; Takai M; Kawata K; Horie K; Kikuchi M; Kato T; Mizutani K; Seike K; Tsuchiya T; Yasuda M; Yokoi S; Nakano M; Ushikoshi H; Miyazaki T; Deguchi T
Hinyokika Kiyo; 2015 Sep; 61(9):347-51. PubMed ID: 26497860
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and Safety of Selective Vascular Endothelial Growth Factor Receptor Inhibitors Compared with Sorafenib for Metastatic Renal Cell Carcinoma: a Meta-analysis of Randomised Controlled Trials.
Kang SK; Volodarskiy A; Ohmann EL; Balar AV; Bangalore S
Clin Oncol (R Coll Radiol); 2016 May; 28(5):334-41. PubMed ID: 26723100
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]